Penn Cardiovascular Institute

Penn Cardiovascular Institute Research Directory

faculty photo

Emer M. Smyth, Ph.D.

Research Associate Professor of Pharmacology
Department: Pharmacology
Graduate Group Affiliations

Contact information
Institute for Translational Medicine and Therapeutics
3400 Civic Center Blvd
Building 421, 10th floor, Room 104
University of Pennsylvania
Philadelphia, PA 19104
Office: (215) 573-2323
Fax: (215) 573-9135
Education:
B.Sc. (First Class Honor in Pharmacology)
National University of Ireland, University College, Dublin , 1990.
Ph.D. (Pharmacology)
National University of Ireland, University College, Dublin, Ireland, 1994.
Permanent link
 
> Perelman School of Medicine   > Faculty   > Details

Description of CVI Expertise

CVI Program Unit(s):
Lipid / Atherosclerosis / CAD / ACS / Prevention
Thrombosis / Hemostasis

CVI Research Description:

Prostanoids, a family of lipid mediators with multiple and diverse biological actions, are formed by the action of cyclooxygenase (COX) on arachidonic acid. A single gene product, encoding a G protein coupled receptor (GPCR) has been identified for prostacyclin (the IP), PGF2α (the FP) and TxA2 (the TP), while four distinct GPCRs for PGE2 (the EP1-4), and two for PGD2 (DP1 and DP2), have been cloned.

Our laboratory is interested in the novel pathways directing the function and regulation of prostanoid receptors. Over the past decade the paradigm of GPCR homo- and hetero- dimerization has become and accepted phenomenon. We have show association of the IP and TP to form homo- and hetero- dimers with consequent changes in TP signaling and regulation. More recently we have identified formation of DP1 and DP2 homo- and hetero- dimers (but not IP-DP heterodimers) at comparable affinities. Currently we are investigating the molecular and cellular events that regulate prostanoid receptor dimerization in normal settings and cardiovascular disease.

A second major resarch focus of our laboratory emerged from the recent interest in the inducible COX-2 isoform as a chemopreventative or chemotherapsutic target in human cancer. Epidemiological reports demonstrate a reduction in the risk of mammary cancer with co-incident used of COX inhibitors. Our research examines the role of COX-1 and COX-2, in mammary cancer, and cancer related thrombosis, using mice engineered to lack specifically COX-2 expression the mammary epitheilium. Inititation, progression and metastasis of mammary tumors, and the incidence of cancer-related venous thrombosis, is currently under examination.

Selected Publications

Frey, AJ Ibrahim, S, Gleim, S, Hwa, J and Smyth, EM: Biased Suppression of Thromboxane A2 Receptor Homodimerization and Signaling Through Disruption of a Transmembrane GxxxGxxxL Helical Interaction Motif. J Lipid Rresearch 54(6): 1678-1690, Jun 2013.

Ibrahim, S, Markosyan, N, McCartney, A, and Smyth, EM: Heterodimerization With The Prostacyclin Receptor Triggers Thromboxane Receptor Relocation to Lipid Rafts. Arterioscler. Thrombosis. Vasc. Biol. 33: 60-66, Jan 2013.

Markosyan N, Chen EP, Evans RA, Ndong N, Vonderheide RH and Smyth EM.: Mammary carcinoma cell derived cyclooxygenase 2 suppresses tumor immune surveillance by enhancing intratumoral immune checkpoint activity. Breast Cancer Research in press, 2013.

Siangjong L, Gauthier KM, Pfister SL, Smyth EM, Campbell WB: Endothelial 12(S)-HETE vasorelaxation is mediated by thromboxane receptor inhibition in mouse mesenteric arteries. Am J Physiol Heart Circ Physiol 304(3): H382-392, 2013.

Nune Markosyan; Edward Chen; Victoire Ndong; Yubing Yao; Christopher J. Sterner; Lewis A. Chodosh; John A. Lawson; Garret A. FitzGerald; Emer M. Smyth: Deletion of cyclooxygenase 2 in mouse mammary epithelial cells delays breast cancer onset through augmentation of type 1 immune responses in tumors Carcinogenesis Page: in press, 2011.

Salam I, Tetruashvily M, Frey AJ, Wilson SJ, Stitham J, Hwa J, Smyth EM: Dominant negative actions of human prostacyclin receptor variant through dimerization: Implications for cardiovascular disease. Arteriosclerosis, Thrombosis, and Vascular Biology 30(9): 1802-1809, 2010.

Wilson SJ, Cavanagh CC, Lesher AM, Frey AJ, Russell SE, Smyth EM: Activation-dependent stabilization of the human thromboxane receptor: Role of reactive oxygen species. J Lipid Res 50(6): 1047-1056, Jun 2009.

McGillicuddy FC, Chiquoine EH, Hinkle CC, Kim RJ, Shah R, Roche HM, Smyth EM, Reilly MP: Interferon gamma attenuates insulin signaling, lipid storage, and differentiation in human adipocytes via activation of the JAK/STAT pathway. J Biol Chem 284(46): 31936-31944, 2009.

Yu Y, Lucitt MB, Stubbe J, Cheng Y, Friis UG, Hansen PB, Jensen BL, Smyth EM, FitzGerald GA: Prostaglandin F2alpha elevates blood pressure and promotes atherosclerosis. Proc Natl Acad Sci USA 106(19): 7985-7990, 2009.

Wada M, DeLong CJ, Hong YH, Rieke CJ, Song I, Sidhu RS, Yuan C, Warnock M, Schmaier AH, Yokoyama C, Smyth EM, Wilson SJ, FitzGerald GA, Garavito RM, Sui DX, Regan JW, Smith WL: Enzymes and receptors of prostaglandin pathways with arachidonic acid-derived versus eicosapentaenoic acid-derived substrates and products. J Biol Chem 282(31): 22254-22266, Aug 2007.

back to top
Last updated: 07/12/2013
The Trustees of the University of Pennsylvania